| Literature DB >> 32185462 |
Lena Bilet1,2, Esther Phielix1,2, Tineke van de Weijer1,2,3, Anne Gemmink1,2, Madeleen Bosma1,2, Esther Moonen-Kornips1,2, Johanna A Jorgensen1,2, Gert Schaart2, Dongyan Zhang4, Kenneth Meijer1,2, Maria Hopman5, Matthijs K C Hesselink1,2, D Margriet Ouwens6, Gerald I Shulman4,7, Vera B Schrauwen-Hinderling1,2,3, Patrick Schrauwen8,9.
Abstract
AIMS/HYPOTHESIS: Physical inactivity, low mitochondrial function, increased intramyocellular lipid (IMCL) deposition and reduced insulin sensitivity are common denominators of chronic metabolic disorders, like obesity and type 2 diabetes. Yet, whether low mitochondrial function predisposes to insulin resistance in humans is still unknown.Entities:
Keywords: Fat oxidation; Insulin resistance; Intramyocellular lipid content; Mitochondrial function; Mitochondrial oxidative capacity; Physical inactivity; Unilateral lower-limb suspension
Year: 2020 PMID: 32185462 PMCID: PMC7228997 DOI: 10.1007/s00125-020-05128-1
Source DB: PubMed Journal: Diabetologia ISSN: 0012-186X Impact factor: 10.122
Participant characteristics (n = 10), as measured before ULLS
| Characteristic | Mean ± SEM |
|---|---|
| Age (years) | 22.4 ± 4.2 |
| BMI (kg/m2) | 21.3 ± 2.0 |
| Fat (%) | 14.6 ± 3.9 |
| Systolic blood pressure (mmHg) | 115 ± 12 |
| Diastolic blood pressure (mmHg) | 74 ± 11 |
| Plasma glucose (mmol/l) | 4.9 ± 0.3 |
| Plasma TAGs (mmol/l) | 1.0 ± 0.4 |
| Plasma NEFA (mmol/l) | 0.4 ± 0.2 |
| 48 ± 10 |
Fig. 1(a) Study design and (b) ULLS set up. Image in (b) from Berg et al. [23], reprinted with permission from the American Physiological Society. DEXA, dual energy x-ray absorptiometry
Fig. 2Participant compliance to the intervention as measured with (a) activity monitors (accelerometers) (n = 4–9) and (b) temperature sensors (n = 9). *p < 0.05. Data expressed as mean ± SEM
Fig. 3Mitochondrial oxidative capacity and incorporation of labelled palmitate into DAG and TAG in the active vs the suspended leg, post-suspension, in the overnight fasted state. (a–c) Mitochondrial oxidative capacity expressed as (a) PCr-recovery T1/2 in vivo (n = 10), and (b,c) ex vivo [14C]palmitate oxidation to CO2 (b; n = 9) and ASMs (c; n = 9). (d, e (both n = 9) [14C]palmitate incorporation into TAGs (d) and DAGs (e). *p < 0.05
Fig. 4(a) In vivo IMCL in the musculus tibialis anterior, measured by 1H-MRS, in the active vs the suspended leg, post-suspension, in the overnight fasted state (n = 9). (b) Ex vivo IMCL in musculus vastus lateralis, measured with Oil Red O staining, in the overnight fasted state (n = 6). *p < 0.05, **p < 0.01
Fig. 5Ratio of PKCθ in the muscle membrane:cytosol (a measure of PKCθ activation) in the overnight fasted state. Representative blots are also shown (a, active; s, suspended). n = 8; *p < 0.05
Fig. 6Plasma concentrations of (a) NEFA (n = 10; data expressed as mean ± SEM) and (b) glucose during the insulin+lipid infusion (n = 10). ***p < 0.001, compared with baseline (time [t]0)
Fig. 7The expression level of (a) insulin receptor, (b) p-IRS1Ser1101, (c) p-AktThr308, (d) p-AktSer473, (e) PDK4, (f) p-GSSer641, (g) p-GSK3βSer9, (h) p-FOXO (FOXO1Thr24/FOXO3aThr32), (i) p-AMPKThr172 and (j) p-ACCSer79 in the active vs the suspended leg, in the insulin-stimulated state. Representative blots also shown (a, active; s, suspended). n = 8; *p < 0.05